Fact CheckerSign in

NCT07492524Recruiting

A Village Doctor-led Telehealth Supported Improvement of Outcomes of AF Patients With Heart Failure Due to Reduced or Preserved Ejection Fraction: The MIRACLE-AF 2 Heart Failure Management Trial (MIRACLE AF-HF)

Source: ClinicalTrials.gov · Last updated 7 Oct 2026

Brief summary (registry, in English)

The primary objective is to determine whether a telemedicine-supported, village doctor-led integrated management model, AF-HF comorbidity ABC pathway and enhanced patient education, improves clinical outcomes compared with usual care among rural residents aged 65-80 years with AF and HF. The trial will evaluate whether integrated management reduces the MAGGIC HF risk score at 12 months (phase 1) and whether it reduces a composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation over 36 months (phase 2). An extended observational follow-up, the composite cardiovascular endpoint observational follow-up study, will be conducted at Year 6 to evaluate long-term effects.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
942 (estimated)
First submitted
16 Mar 2026
Start date
26 Jul 2026
Primary completion date
30 Dec 2032
Lead sponsor
Jiangsu Taizhou People's Hospital
NCT number
NCT07492524

What you commit to

  • Study type: Interventional
  • Planned participants: 942
  • From 26 Jul 2026 to the primary completion date, 30 Dec 2032
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Severe renal insufficiency (Ccr \< 30ml/min) or ongoing dialysis treatment.
  • Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
  • Chronic obstructive pulmonary disease (COPD) complicated by type II respiratory failure.
  • Special populations, including patients with mental illnesses.

Other

  • Expected life expectancy of less than 12 months.
  • Indications for pacemaker implantation without having undergone implantation.

Age in the registry: 65 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Village Clinics in Suining County, Jiangsu Province
Coordinator of this site? Confirm its status
XuzhouChinaRecruiting
Village Clinics in Dongtai City, Jiangsu Province
Coordinator of this site? Confirm its status
YanchengChinaRecruiting
Village Clinics in Jiangdu District, Jiangsu Province
Coordinator of this site? Confirm its status
YangzhouChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.